Lipocine (LPCN) Times Interest Earned (2013 - 2025)
Lipocine's (LPCN) quarterly Times Interest Earned came in at -$21.38 in Q3 2025, up 89.38% YoY from -$11.29 in Q3 2024, and down 123.66% on a QoQ basis from -$9.56 in Q2 2025.
Lipocine (LPCN) Times Interest Earned (2013 - 2025) Analysis & Trends
Lipocine (LPCN) has 13 years of Times Interest Earned data on file, last reported at -$21.38 in Q3 2025.
- Quarterly Times Interest Earned rose 89.38% year-over-year to -$21.38 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$40.14 (up 90.09% YoY) and the FY2024 annual result came in at -$0.02, up 93.61% from the prior year.
- Times Interest Earned retreated to -$21.38 in Q3 2025, from -$9.56 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $535.5 in Q4 2021 to a low of -$1972.1 in Q4 2023.
- A 5-year average of -$93.3 and a median of -$13.24 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2021 — Times Interest Earned surged 2559.66% — and 2023, when it plunged 5052.21%.
- Tracing LPCN's Times Interest Earned over 5 years: stood at $535.5 in 2021, then plunged by 107.15% to -$38.28 in 2022, then sank by 5052.21% to -$1972.1 in 2023, then surged by 100.18% to $3.52 in 2024, then sank by 706.81% to -$21.38 in 2025.
- The last three Times Interest Earned figures came in at -$21.38 (Q3 2025), -$9.56 (Q2 2025), and -$6.04 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -21.38 |
| Jun 30, 2025 | -9.56 |
| Mar 31, 2025 | -6.04 |
| Dec 31, 2024 | 3.52 |
| Sep 30, 2024 | -201.28 |
| Jun 30, 2024 | -14.30 |
| Mar 31, 2024 | 86.49 |
| Dec 31, 2023 | -1,972.13 |
| Sep 30, 2023 | -47.30 |
| Jun 30, 2023 | -16.60 |
| Mar 31, 2023 | -13.24 |
| Dec 31, 2022 | -38.28 |
| Sep 30, 2022 | -20.25 |
| Jun 30, 2022 | -15.40 |
| Mar 31, 2022 | -4.70 |
| Dec 31, 2021 | 535.50 |
| Sep 30, 2021 | -9.23 |
| Jun 30, 2021 | -4.70 |
| Mar 31, 2021 | -3.79 |
| Dec 31, 2020 | 20.13 |